Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 11, 2025 16:05 ET | Source: Rapport Therapeutics, Inc.

Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

BOSTON and SAN DIEGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and...
September 08, 2025 06:00 ET | Source: Rapport Therapeutics, Inc.

Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures

Rapport Announces Positive Topline Results from Phase 2a Clinical Trial of RAP-219 in Patients with Focal Onset Seizures
August 07, 2025 07:00 ET | Source: Rapport Therapeutics, Inc.

Rapport Therapeutics Reports Second Quarter 2025 Financials and Provides Business Update

RAP-219 Phase 2a trial in patients with drug-resistant focal onset seizures is fully enrolled and on track for topline results in September 2025Phase 2 trial of RAP-219 in bipolar mania has been...
April 22, 2025 07:00 ET | Source: Rapport Therapeutics, Inc.

Rapport Therapeutics to Participate in Upcoming Investor Conferences

Rapport Therapeutics to Participate in Upcoming Investor Conferences
March 03, 2025 07:00 ET | Source: Rapport Therapeutics, Inc.

Rapport Therapeutics Announces Appointment of Dr. Jeffrey Sevigny as Chief Medical Officer to Drive Clinical Strategy and Precision Medicine Development

Rapport appoints Dr. Jeffrey Sevigny as CMO, a physician-scientist with more than 15 years of translational and clinical drug development